ERBB2 and neoplasm: Bose et al. found that HER2 R678Q, I767M, and Y835F mutations exerted no functional effects, while HER2 G309A, L755S, D769H/Y, V777L, P780_781insGSP, V842I, and R896Q mutations resulted in increased HER2 signaling and increased tumor growth in the preclinical study.12